If the FDA wants all the major uncertainties settling (MACE, CHF, CKD, and cognitive function) it might need a trial that is larger and/or longer than BETonMACE with what's called a randomised block design to ensure that subgroups of interest are of sufficient size and well matched for other relevant variables. On the other hand, they might also opt for two or three smaller studies targeting different questions.